News und Analysen
The Smartest Move Johnson & Johnson Has Made All Year
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a stalwart in the portfolios of risk-averse, income-seeking long-term investors. It's about as rock-solid as they....
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE: PFE) Xtandi quickly gained ground on Johnson &....
3 Reasons Why Gilead Sciences Stock Is a Buy Now
Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent....
Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
A head-to-head competition for market share in the renal cell carcinoma (RCC) market appears to be about to intensify. In one corner is Bristol-Myers Squibb (NYSE: BMY). With a market cap of over....
How Much Does It Really Cost to Develop a Cancer Drug?
Cancer drugs can cost hundreds of thousands of dollars and increasing complexity suggests that prices for these drugs are going higher. For instance, Novartis (NYSE: NVS) won approval for a new....
3 Dividend Healthcare Stocks
One great reason to consider buying healthcare stocks is that demand for their products tends to remain stable in good times and bad. After all, no one gets to choose when they get sick. That....
Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today
The stock market was once again mixed on Thursday, with the Dow Jones Industrials gaining ground to set a record high for the third session in a row even as other major benchmarks lagged behind.....
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Take your seats, investors: The battle in first-line advanced renal cell carcinoma, the most common type of kidney cancer, is about to begin.In one corner, weighing in at a market cap of $8....
Why Lexicon Pharmaceuticals Is Down 11% Today
After Lexicon Pharmaceuticals (NASDAQ: LXRX) announced yesterday the publication of phase 3 results for its lead diabetes drug, sotagliflozin, in the New England Journal of Medicine, its shares....
Here's Why Glaukos Corp. Stock Is Stumbling Today
Shares of Glaukos Corp. (NYSE: GKOS), a medical device manufacturer with an eye on glaucoma, are slipping today. Just ahead of the company's investors day meeting, management made some adjustments....
Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
Shares of Halozyme Therapeutics (NASDAQ: HALO), a small-cap biotech focused on creating products that help other drugs work more effectively, rose by 16% as of 10:45 a.m. EDT on Thursday.....
How Safe Is Abbott Labs' Dividend?
Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. For much of its history, Abbott was a true healthcare conglomerate, producing both....
Here's Why the Best Is Yet to Come for Opko Health Inc.
There's not a whole lot that looks good for Opko Health Inc. (NASDAQ: OPK) right now. The stock has dropped more than 30% so far in 2017. Several large institutional investors have reduced their....
3 Biotech Stocks That Have Already Quadrupled in 2017
It's been a good year for biotech stocks, the iShares Nasdaq Biotechnology index has risen about 26% this year but a handful of companies make the industry tracking index's success seem trivial.....
Why Equifax Inc Stock Dropped 12% Today
Shares of consumer credit bureau Equifax Inc. (NYSE: EFX) are down by about 12% as of 3:10 p.m. EDT as the company deals with fallout from a data breach that exposed the personal information --....
Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
Gilead Sciences' (NASDAQ: GILD) share repurchases last year could only be classified as horrible: The company bought back shares between $83.33 and $100 per share as the stock dropped....
Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
Regeneron Pharmaceuticals (NASDAQ: REGN) unveiled phase 3 study data for its autoimmune disease drug Dupixent earlier this week that show it is effective in treating asthma. The success has....
5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing
What's the best dividend stock in all of big pharma? I would argue that the hands-down winner is AbbVie (NYSE: ABBV). The big biotech has the total package for dividend-seeking investors: a high....
Is the Sell-Off of Intercept Pharmaceuticals Stock Overblown?
Last year, a letter written by Chinese scholar Zeng Gong in 1080 sold for more than $30 million. It became the world's most expensive letter. However, a letter issued by Intercept Pharmaceuticals....
3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
It's been a great 2017 for Amgen (NASDAQ: AMGN) shareholders so far. Amgen stock is up close to 30%. The company announced several positive developments from its pipeline. Still, though, some....
Why Shares of Inovalon Are Soaring Today
Shares of cloud-based healthcare platform provider Inovalon (NASDAQ: INOV) jumped on Tuesday after the company announced that UnitedHealthcare, a business of UnitedHealth Group (NYSE: UNH), had....
Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today
Shares of Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotech developing novel cancer immunotherapies, are sinking after the company provided a business update along with a third-quarter....
2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term
There's a lot for investors to really like about Vertex Pharmaceuticals (NASDAQ: VRTX). The company reached profitability earlier this year. It has reported a string of positive clinical results....
5 Things Regeneron's CEO Said as the Biotech Stock Sank
Regeneron (NASDAQ: REGN) CEO Leonard Schleifer was on the hot seat Monday at the Morgan Stanley healthcare conference. And the timing was either terrific or terrible, depending on your....
3 Stocks for Future Millionaires
If you have a desire to be a millionaire someday -- I mean, come on, you're reading about investing. Of course, you're interested -- then one of the best ways to get there is to invest in great....